Aldosterone antagonists: The most underutilized class of heart failure medications

American Journal of Cardiovascular Drugs

Volumn 7, Issue 1, 2007, Pages 75-79

  Guglin, Maya ^a   Awad, Khaled Esmaeel ^a   Polavaram, Latha ^a   Vankayala, Hema ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; FUROSEMIDE; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG UTILIZATION; FEMALE; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; RETROSPECTIVE STUDY; SYSTOLIC DYSFUNCTION; TREATMENT INDICATION;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGE FACTORS; AGED; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; INPATIENTS; MALE; MIDDLE AGED; PATIENT DISCHARGE; QUESTIONNAIRES; SPIRONOLACTONE;

EID: 34247869030     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200707010-00007     Document Type: Article

References (26)

1. Trujillo JM, Gonyeau MJ, DiVall MV, et al. Spironolactone use in patients with heart failure. J Clin Pharm Ther 2004; 29 (2): 165-70
2. Philbin EF. Factors determining angiotensin-converting enzyme inhibitor underutilization in heart failure in a community setting. Clin Cardiol 1998; 21 (2): 103-8
3. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure: the SOLVD Investigators. N Engl J Med 1991; 325 (5): 293-302
4. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-55
5. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure [MERIT-HF]. Lancet 1999; 353 (9169): 2001-7
6. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341 (10): 709-17
7. Horwich T, Smooke S, Hamilton M, et al. Analysis of triple drug therapy in heart failure: cumulative benefit? J Card Failure 2003; 9 (1 Suppl. 5): S102
8. Faggiano P, Opasich C, TavazziL, et al. IN-CHF Investigators. Prescription patterns of diuretics in chronic heart failure: a contemporary background as a clue to their role in treatment. J Card Fail 2003; 9 (3): 210-8
9. Boyles PJ, Peterson GM, Bleasel MD, et al. Undertreatment of congestive heart failure in an Australian setting. J Clin Pharm Ther 2004; 29 (1): 15-22
10. Komajda M, Follath F, Swedberg K, et al., Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure Survey Programme: a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003; 24 (5): 464-74
11. Pereira Barretto AC, Cuce Nobre MR, Lancarotte I, et al. Do cardiologists at a university hospital adopt the guidelines for the treatment of heart failure? [in Portuguese]. Arq Bras Cardiol 2001; 77 (1): 30-6
12. Roman-Sanchez P, Conthe P, Garcia-Alegria J, et al. Factors influencing medical treatment of heart failure patients in Spanish internal medicine departments: a national survey. QJM 2005; 98 (2): 127-38
13. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol 2003; 41 (1): 56-61
14. Muntwyler J, Cohen-Solal A, Freemantle N, et al. Relation of sex, age and concomitant diseases to drug prescription for heart failure in primary care in Europe. Eur J Heart Fail 2004; 6 (5): 663-8
15. Ahmed A, Allman RM, DeLong JF, et al. Age-related underutilization of angiotensin-converting enzyme inhibitors in older hospitalized heart failure patients. South Med J 2002; 95 (7): 703-10
16. Patel JA, Fotis MA. Comparison of treatment of patients with congestive heart failure by cardiologists versus noncardiologists. Am J Health Syst Pharm 2005; 62 (2): 168-72
17. Rutten FH, Grobbee DE, Hoes AW. Differences between general practitioners and cardiologists in diagnosis and management of heart failure: a survey in everyday practice. Eur J Heart Fail 2003; 5 (3): 337-44
18. Chin MH, Friedmann PD, Cassel CK, et al. Differences in generalist and specialist physicians' knowledge and use of angiotensin-converting enzyme inhibitors for congestive heart failure. J Gen Intern Med 1997; 12 (9): 523-30
19. McKee PS, Leslie SJ, LeMaitre JP, et al. Management of chronic heart failure due to systolic left ventricular dysfunction by cardiologist and non-cardiologist physicians. Eur J Heart Fail 2003; 5 (4): 549-55
20. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol 2003; 41 (2): 211-4
21. Masoudi FA, Gross CP, Wang Y, et al. Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001. Circulation 2005; 112 (1): 39-47
22. Sligl W, McAlister FA, Ezekowitz J, et al. Usefulness of spironolactone in a specialized heart failure clinic. Am J Cardiol 2004; 94 (4): 443-7
23. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 35 (6): 543-51
24. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2005; (112): e154-235
25. McMurray JJV, Young JB, Dunlap ME, et al. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. Am Heart J 2006; 151: 985-91
26. Pitt B. Generic drugs in cardiology: will they reduce health care costs? J Am Coll Cardiol 2004; 44 (1): 10-3